Naxan (Naloxone Hydrochloride)

Naloxone Hydrochloride, the active ingredient in Naxan, is an opioid antagonist presented as a sterile injectable solution for intramuscular, intravenous, and subcutaneous use. It rapidly reverses the effects of opioid overdose in adults and children by displacing opioid molecules from mu‑receptors, restoring breathing and consciousness. The formulation is supplied in single‑dose vials suitable for emergency settings.

GNH USA supplies Naxan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable cold‑chain logistics where required.

Naloxone acts on the opioid receptor system to rapidly reverse opioid‑induced respiratory depression and loss of consciousness.

- Opioid overdose: provides rapid restoration of normal breathing and consciousness by displacing opioid agonists from mu‑opioid receptors, typically within minutes. - Opioid toxicity: reverses central nervous system depression caused by accidental or intentional opioid exposure, helping to re‑establish alertness and protective reflexes. - Acute opioid‑induced respiratory depression: restores adequate ventilation and oxygenation in emergency settings, reducing the risk of hypoxic injury. - Opioid‑related cardiac depression: improves heart rate and blood pressure by counteracting opioid‑mediated bradycardia and hypotension.

Naloxone may be associated with a range of adverse reactions, most of which are transient and related to abrupt opioid reversal.

Common Side Effects: - Nausea - Vomiting - Sweating - Tachycardia - Hypertension - Agitation

Serious or Rare Side Effects: - Seizures - Severe hypertension - Pulmonary edema - Anaphylaxis - Cardiac arrest

When using Naloxone, several safety considerations should be observed to ensure effective and safe reversal of opioid toxicity.

- Assess airway and breathing: confirm opioid overdose before administration. - Monitor vital signs: observe heart rate, blood pressure, and respiratory status after dosing. - Use only in opioid overdose situations: avoid routine use in patients without opioid exposure. - Adjust dose in cardiovascular disease: be cautious in patients with coronary artery disease or hypertension. - Avoid intravascular injection when possible: ensure proper intramuscular, subcutaneous, or intravenous technique. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Naloxone can interact with other medications, influencing its efficacy or the safety profile of co‑administered drugs.

Major Interactions (Avoid): - Concurrent high‑dose opioid agonists: may diminish naloxone’s reversal effect. - Co‑administration with other opioid antagonists: can lead to additive precipitated withdrawal.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia that signals adverse reaction. - Sedatives or benzodiazepines: may enhance central nervous system effects after reversal. - Monoamine oxidase inhibitors: may increase risk of hypertensive response.